Session Details

Wednesday Posters - Depression

Wednesday, 11 February 2004 16:00 -17:00

Hall 5, Exhibition Halls

Posters will be on display from Tuesday, 10 February until Thursday, 12 February.

Presenters will be in attendance to discuss their posters in this topic between 16:00-17:00 on Wednesday, 11 February.

Epidemiology of major depressive disorder in Latin America: Baseline demographic results of a 1 year observational study (H6U-BC-LRAG & H6U-BL-LRAH)
  • Dr Margaret E McBride, Clinical Outcomes Research Institute, Eli Lilly Australia Pty Limited, Australia
    • The prevalence of depression and birth weight. A register study
  • Jens Knud Larsen, Gentofte Psychiatric Centre, Denmark
    • Hypoalbuminemia in patients with major depressive disorder compared with a dietary matched control group: A clinical meaning beyond malnutrition
  • Kuan-Pin Su, China Medical University and Hospital, Taichung, Taiwan
    • The importance of Erythropoetin in the treatment of depression observed during hemodialysis of patients with chronic failure
  • Meltem Efe Sevim, Turkey
    • Serum albumin and ferritin levels in chronic hemodialysis patients with or without major depression
  • Tiao-Lai Huang, Chang Gung Memorial Hospital at Kaohsiung, Taiwan
    • A study comparing patients with different kind of neuromuscular disorders on measures of quality of life, depression, and anxiety
  • Sukru Uguz, Cukurova University, Turkey
    • Some peculiarities of treatment affective disorders comorbid with organic behavioral disorders due to consequences of radiation environment
  • Dr Galyna G Shurenok, Kiev City Psychiatrical Hospital No 3, Ukraine
    • Combined proteomic/microarray approach to identify novel candidate genes for individual variation in response to antidepressants
  • Dr Geraldine R Rogers, Christchurch School of Medicine and Health Sciences, New Zealand
    • CYP 2D6*10 alleles do not determine plasma Fluvoxamine concentration/dose ratio in Japanese
  • Koichi Ohara, Kanagawa Center for Psychiatry, National Minami Hanamaki Hospital, Japan
    • Doxepin inhibits CYP2D6 activity in vivo
  • Monika Szewczuk-Boguslawska, University of Medicine, Poland
    • Triiodothyronine (T3) augmentation of SSRI resistant depression
  • Gaby Abraham, Queen's University, Kingston Ontario, Canada
    • Comparison of sexual functioning in patients receiving Duloxetine or Paroxetine: Acute- and long-term data
  • Michael J Detke, Eli Lilly and Company; Indiana University Medical School, United States
    • Duloxetine vs. Placebo in the prevention of relapse of major epressive disorder
  • Michael J Detke, Eli Lilly and Company; Indiana University Medical School, Indianapolis, United States
    • Remission in placebo-controlled trials of Duloxetine with an SSRI comparator
  • Michael J Detke, Eli Lilly and Company, United States
    • Safety profile of Duloxetine vs. Paroxetine
  • Michael J Detke, Eli Lilly and Company; Indiana University Medical School, United States
    • Onset of improvement in emotional and painful physical symptoms of depression with Duloxetine treatment
  • Michael J Detke, Eli Lilly and Company; Indiana University Medical School, United States
    • A comparison of remission rates based on Ham-D 17 subscales using MMRM and LOCF method for modelling missing data
  • Richard Entsuah, Wyeth Research, United States
    • Remission in depressed patients treated with Venlafaxine XR or SSRIS using treatment algorithms
  • Isma Benattia, Wyeth Research, United States
    • A comparison of Venlafaxine, SSRIS, and placebo in improving fatigue in patients with major depression
  • Rajiv Mallick, Wyeth Research, United States
    • Venlafaxine vs SSRIS: Comparison of somatic symptom resolution
  • Richard Entsuah, Wyeth Research, United States
    • Comprehensive pooled analysis of remission data: Venlafaxine vs SSRIS (Compare)
  • Charles Nemeroff, Emory University School of Medicine, United States
    • Short term and long term effects of Mirtazapine and Venlafaxine on sleep-EEG in patients with major depression
  • Dr Ulrich M Hemmeter, Psychiatric University Clinic Marburg, Germany
    • Factor analysis of the onset of therapeutic effect of mirtazapine vs SSRIs: a meta-analysis on data of more than 2500 patients
  • Dr Elizabeth Barilla, Organon Australia, Australia
    • Mirtazapine versus SSRIs: A meta-analysis on the onset of antidepressant activity in more than 2500 patients with major depression
  • MSc Arjen PP van Willigenburg, NV Organon, The Netherlands
    • Remission with mirtazapine versus SSRIs in the treatment of depression: A meta-analysis on data of more than 2500 patients
  • Albert Jan Schutte, United States
    • Remission of early responders in patients with major depression treated with Mirtazapine
  • Ho-Suk Suh, Pochon CHA University, College of Medicine, Korea
    • Paroxetine CR efficacy and tolerability at low doses in the treatment of major depression
  • Cornelius D Pitts, GlaxoSmithKline, United States
    • Paroxetine improves the functional disability associated with mood and anxiety disorders
  • Dr David Briess, GlaxoSmithKline, United Kingdom
    • Paroxetine improves sleep disturbances in patients with major depression and anxiety disorders
  • Dr Eric M Dube, GlaxoSmithKline, United States
    • Paroxetine improves somatic pain associated with physical illness in patients with and without comorbid depressive or anxiety disorders
  • Dr David A Duff, GlaxoSmithKline, United Kingdom
    • Tolerability and pharmacokinetics of controlled and immediate release paroxetine in the treatment of major depression and anxiety disorders
  • Dr Phil Perera, GlaxoSmithKline, United States
    • Efficacy and tolerability of controlled release Paroxetine in the treatment of severe depression
  • Dr David J Carpenter, GlaxoSmithKline, United States
    • Efficacy of Paroxetine controlled-release (CR) and immediate-release (IR) formulations in the elderly
  • Cornelius D Pitts, GlaxoSmithKline, United States
    • The pharmacological treatment of late-life depression
  • Dana Ignjatovic, Non Governmental Psychiatric Health Clinic, Slovak Republic
    • Escitalopram: Effective and better tolerated than venlafaxine XR in the treatment of depression
  • J Bothmer, Lundbeck GmbH & Co, Germany
    • Switching depressed patients from Citalopram to Escitalopram treatment is safe and effective
  • A Wade, CPS Clinical Research Centre, United Kingdom
    • Depression in primary care patients: Escitalopram is safe and well tolerated in long-term treatment
  • A Wade, CPS Clinical Research Centre, United Kingdom
    • Escitalopram versus citalopram: More efficacious and well tolerated in long-term treatment of moderately depressed patients
  • F Menard, H. Lundbeck SA, France
    • Escitalopram (10 to 20mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care
  • F Menard, H. Lundbeck SA, France
    • Fixed dose of escitalopram (10mg/day) and a flexible dosing regimen of sertraline (50-200mg/day) in a randomised, double-blind comparison in depressed patients
  • S M Lenz, H. Lundbeck A/S, Denmark
    • Double-blind comparison of escitalopram and venlafaxine XR in the treatment of major depressive disorder
  • J Bothmer, Lundbeck GmbH & Co, Germany